ClinicalTrials.gg
RecruitingNCT05878574Updated May 26, 2023

Prospective Study of BMD and Ca-P Metabolism in RSA Patients: LMWH Use Versus Control

An observational study in Recurrent Spontaneous Abortion, sponsored by Aimin Zhao. Recruiting at 1 site in China. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-26.

Sponsored by Aimin Zhao · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 11 months ago, but the record still lists the study as recruiting.
  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
344
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Abortion, Spontaneous with a site in China — 4 open to participants now, 4 under way, none of them phase 3. Abortion, Spontaneous · China.

Planned enrollment
4th of 12
344 · median 200
Started
2022
with 2 others
Observational
12 of 15
2 open now
Registered
9th of 15
by date
Lead sponsor
2 of 15
Aimin Zhao

Among the 15 studies in Abortion, Spontaneous with a site in China, this one is the 4th largest by planned enrollment of the 12 observational ones that give a count, is one of 3 that started in 2022, is one of 12 observational ones, and was the 9th registered.

Abortion, Spontaneous

221 studies on the registry are indexed under Abortion, Spontaneous; 44 are open to participants now.

Browse Abortion, Spontaneous studies →

Open to participants now

4 of the 15 studies in Abortion, Spontaneous with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 36 Abortion, Spontaneous studies recruiting now, 11 (31%) set no upper age limit and 25 (69%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Abortion, Spontaneous with a site in China, or all of them as a file.
02

Study summary

The goal of this prospective observational study is to learn about the effect of low molecular weight heparin (LMWH) application on bone mineral density (BMD) and on calcium-phosphorus metabolism in patients with recurrent spontaneous abortion (RSA), and to compare the degree of bone loss and changes in blood calcium and phosphorus in RSA patients and in control groups with normal pregnancy. By monitoring ultrasound BMD and serum indicators related to maternal bone formation and Ca-P metabolism, the association mechanism between long-term use of LMWH, maternal Ca-P regulation and bone loss will be constructed, so as to contribute to clinical treatment and lifestyle guidance during pregnancy in RSA patients.

Read the detailed description

Women who meet the inclusion criteria at the outpatient clinic of Renji Hospital are recruited in this study from November 2022 to December 2023. Basic information of all subjects is recorded, including number of miscarriages, duration of breastfeeding, comorbidities, and intake of nutritional supplements. Subjects' medication use during the study is recorded as well. Subjects will undergo ultrasound BMD at six time points: before and after medication during pregnancy preparation, at 10, 24, 32 weeks of pregnancy, and at 42 days postpartum. Peripheral blood will also be collected at the time points above to measure serum osteocalcin, blood calcium, blood phosphorus, 25(OH) D, thyroid hormone, and parathyroid hormone levels. Subjects will be followed up to 42 days postpartum to observe pregnancy outcomes and health conditions of the newborn.

03

Conditions studied

  • Recurrent Spontaneous Abortion

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

All women with a need for pregnancy preparation or a confirmed pregnancy who meet the inclusion criteria from November 2022 to December 2023 at the outpatient clinic of Renji Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 to 45 years.
  • Female who needs to prepare for pregnancy or have a confirmed pregnancy
  • normal karyotype of chromosomes.
  • normal uterine anatomy under pelvic ultrasound examination.
  • Cooperation in completing blood sample collection, testing and ultrasound examination.
  • no serious medical or surgical comorbidities.
  • Sign the form.

Exclusion criteria

Exclusion Criteria:

  • Presence of diseases affecting calcium metabolism, including primary hyperparathyroidism, Cushing's disease, chronic liver, kidney and gastrointestinal (e.g., celiac disease) disorders and rheumatoid arthritis.
  • Known positive and / or screening visit, or antibody positive.
  • The malignant tumors occurred in the past 5 years (except for the skin squamous basal cell carcinoma which has been resected and considered cured). Subjects who developed five years ago should provide evidence of remission or cure. Subjects with a history of cervical cancer who had undergone conization or cure in the past 3 years were eligible.
  • Patients with a history of chronic infection such as Mycoplasma, chlamydia, Cryptococcus and invasive fungal infection should be discussed with the main researchers.
  • History of active tuberculosis (TB) or evidence of previous TB infection. Subjects with a history of potential TB infection should also be excluded, unless there is a documented evidence that they have completed appropriate anti TB treatment in accordance with CDC guidelines or local regulations before screening. In addition, subjects were strictly forbidden to have any clinical symptoms / signs of active TB.
  • Presence of pregnancy .
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
344 participants (estimated)
Patient registry
No

Groups and cohorts

  • LMWH group

    Continuous use of low molecular weight heparin for more than 3 months during pregnancy preparation and during pregnancy with a history of more than 2 consecutive miscarriages before 28 weeks of gestation

    Drug: Low molecular weight heparin

  • control group

    No use of low molecular weight heparin during pregnancy preparation and throughout pregnancy and history of more than 2 consecutive miscarriages before 28 weeks of gestation

Interventions

06

What researchers measure

Primary outcomes

  1. ultrasound BMD before medication during pregnancy preparation

    use ultrasound to test heel bone mineral density before medication during pregnancy preparation

    Time frame: 4 weeks

  2. ultrasound BMD after medication during pregnancy preparation

    use ultrasound to test heel bone mineral density after medication during pregnancy preparation

    Time frame: up to 16 weeks

  3. ultrasound BMD at 10th weeks of pregnancy

    use ultrasound to test heel bone mineral density at 10th weeks of pregnancy

    Time frame: up to 26 weeks

  4. ultrasound BMD at 24th weeks of pregnancy

    use ultrasound to test heel bone mineral density at 24th weeks of pregnancy

    Time frame: 40 weeks

  5. ultrasound BMD at 32nd weeks of pregnancy

    use ultrasound to test heel bone mineral density at 32nd weeks of pregnancy

    Time frame: 1 year

  6. ultrasound BMD at postpartum

    use ultrasound to test heel bone mineral density at postpartum

    Time frame: up to 1 year and 2 months

Secondary outcomes

  1. osteocalcin before medication during pregnancy preparation

    use peripheral blood test to detect N-terminal mid-molecular fragment of serum osteocalcin before medication during pregnancy preparation

    Time frame: 4 weeks

  2. osteocalcin after medication during pregnancy preparation

    use peripheral blood test to detect N-terminal mid-molecular fragment of serum osteocalcin after medication during pregnancy preparation

    Time frame: up to 16 weeks

  3. osteocalcin at 10th weeks of pregnancy

    use peripheral blood test to detect N-terminal mid-molecular fragment of serum osteocalcin at 10th weeks of pregnancy

    Time frame: up to 26 weeks

  4. osteocalcin at 24th weeks of pregnancy

    use peripheral blood test to detect N-terminal mid-molecular fragment of serum osteocalcin at 24th weeks of pregnancy

    Time frame: 40 weeks

  5. osteocalcin at 32nd weeks of pregnancy

    use peripheral blood test to detect N-terminal mid-molecular fragment of serum osteocalcin at 32nd weeks of pregnancy

    Time frame: 1 year

  6. osteocalcin at postpartum

    use peripheral blood test to detect N-terminal mid-molecular fragment of serum osteocalcin at postpartum

    Time frame: up to 1 year and 2 months

  7. calcium before medication during pregnancy preparation

    use peripheral blood test to detect calcium level before medication during pregnancy preparation

    Time frame: 4 weeks

  8. calcium after medication during pregnancy preparation

    use peripheral blood test to detect calcium level after medication during pregnancy preparation

    Time frame: up to 16 weeks

  9. calcium at 10th weeks of pregnancy

    use peripheral blood test to detect calcium level at 10th weeks of pregnancy

    Time frame: up to 26 weeks

  10. calcium at 24th weeks of pregnancy

    use peripheral blood test to detect calcium level at 24th weeks of pregnancy

    Time frame: 40 weeks

  11. calcium at 32nd weeks of pregnancy

    use peripheral blood test to detect calcium level at 32nd weeks of pregnancy

    Time frame: 1 year

  12. calcium at postpartum

    use peripheral blood test to detect calcium level at postpartum

    Time frame: up to 1 year and 2 months

  13. PTH before medication during pregnancy preparation

    use peripheral blood test to detect parathyroid hormone level before medication during pregnancy preparation

    Time frame: 4 weeks

  14. PTH after medication during pregnancy preparation

    use peripheral blood test to detect parathyroid hormone level after medication during pregnancy preparation

    Time frame: up to 16 weeks

  15. PTH at 10th weeks of pregnancy

    use peripheral blood test to detect parathyroid hormone level at 10th weeks of pregnancy

    Time frame: up to 26 weeks

  16. PTH at 24th weeks of pregnancy

    use peripheral blood test to detect parathyroid hormone level at 24th weeks of pregnancy

    Time frame: 40 weeks

  17. PTH at 32nd weeks of pregnancy

    use peripheral blood test to detect parathyroid hormone level at 32nd weeks of pregnancy

    Time frame: 1 year

  18. PTH at postpartum

    use peripheral blood test to detect parathyroid hormone level at postpartum

    Time frame: up to 1 year and 2 months

  19. live bitrh

    A live baby born after 23 weeks of gestation

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Dec 2023, 13 months after the start.

Of 43 observational studies under Abortion, Spontaneous, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 91. This study's planned 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2023
First posted
May 26, 2023
StartActual
Nov 1, 2022
Primary completionEst.
Dec 2023
CompletionEst.
Mar 2024
Last update
May 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05878574
Lead sponsor
Aimin Zhao
Responsible party
Aimin Zhao (Director of Obstetrics and Gynecology, RenJi Hospital) — Sponsor-investigator
First posted
May 26, 2023
Start date
Nov 1, 2022
Primary completion
Dec 2023 (estimated)
Completion
Mar 2024 (estimated)
Last update
May 26, 2023

Study contacts

Daier Yu
Contact
sylviatender@163.com
0086+15000732499
Aimin Zhao, MD
principal investigator · Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion